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ABSTRACT
Cancer is one of themost serious global health concerns in different populations. Several studies indicated that there aremany potentially promising
cellular and molecular targets for cancer therapy within cancer cells and their microenvironment. Among different cellular and molecular targets
involved in cancer pathogenesis, microRNAs (miRNAs) are well known as key targets for cancer therapy. miRNAs are one of main classes of non-
codingRNAs. Thesemolecules play important roles in different critical processes of cancer pathogenesis.Hence, thismakesmiRNAsas a suitable tool
for cancerdiagnosis and therapy.Therearedifferent approaches formonitoringmiRNAs incancerpatients. Someconventional approaches including
next-generation sequencing, real-timepolymerase chain reaction (PCR), northern blotting, andmicroarrays could beused for assessment ofmiRNAs
expression. Some studies revealed that the utilization of these approaches associated with various limitations. Recently, it has been revealed that
molecular imaging techniques are powerful tools for monitoring of different cellular and molecular targets involved in various diseases such as
cancer. These techniques help investigators to investigate andmonitormiRNAs functions through assessing different targets byﬂuorescent proteins,
bioluminescent enzymes, molecular beacons, as well as various nanoparticles. Therefore, utilization of molecular imaging techniques could assist
investigators tobettermonitor andmoreeffectively treatpatientsduringdifferent phasesofmalignancy.Here,wegivea reviewon thecurrent stateof
miRNAs-based imaging techniques in cancer diagnosis and therapy. J. Cell. Biochem. 9999: 1–8, 2017. © 2017 Wiley Periodicals, Inc.
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T o date, cancerhasbeenemergedasoneofmainhealthproblems inworldwide [Faghihloo et al., 2016; Mirzaei et al., 2016a–c].
Despite of recent advances in cancer therapy (such as gene therapy, cell
therapy, andmolecularly-targeted therapies), this disease has remained
as one of the major public health issues worldwide [Mirzaei et al.,
2016d–f, 2017a;Mohammadi et al., 2016a]. Hence, the identiﬁcation of
new targets and molecules involved in cancer, from initiation to
progression and treatment, could contribute in understanding of the
pathways involved in cancer pathogenesis [Arabpour et al., 2016;
Mirzaei et al., 2016e; Simonian et al., 2016]. Theseﬁnding could lead to
development of new and effective treatments in this ﬁeld. One of the
most important mediators in cancer pathogenesis is microRNAs
(miRNAs) [Fathullahzadeh et al., 2016; Mohammadi et al., 2016b;
Gholamin et al., 2017; Mirzaei et al., 2017b; Moridikia et al., 2017].
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MiRNAs are well known as a class of non-coding RNAswhich play key
roles in a wide range of biological processes including development,
cellular differentiation, proliferation, and apoptosis in living organisms
[Ryoo et al., 2013; Gholamin et al., 2016; Rashidi et al., 2016]. The
lengths of these molecules are almost 22 nucleotides [Mirzaei et al.,
2016b]. Several studies indicated that miRNAs have a central role in
pathogenesis of various diseases such as cancer [Gholamin et al., 2017;
Mirzaei et al., 2017a; Moridikia et al., 2017]. Hence, detection and
proﬁling of these molecules could contribute to the better understand-
ing of cancer pathogenesis and, thereby, developing more precise
strategies for early detection and/or treatment of cancer [Zubakov et al.,
2010; Salarini et al., 2015; Gholamin et al., 2016; Mirzaei et al., 2016c].
So far, various conventional approaches such as microarray and RT-
PCRhave beenused formiRNAsdetection in different living systems [Li
and Ruan, 2009; Momin et al., 2009; Hernandez et al., 2013]. These
approaches are associated with some limitations. For example, these
approaches are time-consuming and laborious and required to ﬁx or
lyse the cells and thus cannotmonitor dynamic functions ofmiRNAs in
living cells and organisms (In vivo) [Fang et al., 2006; Lu and Tsourkas,
2009; Ryoo et al., 2013]. To overcome the limitations, developing new
and more efﬁcient, particularly noninvasive repeated quantitative,
methods are the most highly demanded. Recently, some imaging
techniques have been emerged as effective tools for monitoring of
miRNAs [Wangetal., 2009;Hernandezet al., 2013]. Imaging techniques
are well known as powerful tools in monitoring of various targets and
genes in many diseases such as cancer [Wang et al., 2009; Hernandez
et al., 2013]. These techniques could provide new avenue in diagnosis
and treatment of cancer. Various imaging techniques such as magnetic
resonance imaging (MRI), ﬂorescence imaging, and bioluminescence
imaging (BLI) could be used formonitoring and detection ofmiRNAs in
patients with cancer [Wang et al., 2009; Hernandez et al., 2013]. In the
present review, we will not only focus on a variety of miRNAs involved
in cancer pathogenesis but also highlight some recently developed
imagingmethods which assist investigators to detect miRNAs in a high
throughput proﬁling and noninvasive repeated quantitative manner in
preclinical and clinical cancer studies.
MicroRNA AND CANCER
MiRNAs are one of main class of non-coding short RNAs that are
highly conserved [Mirzaei et al., 2016e,b; Mohammadi et al., 2016b].
These RNAs regulate gene expression at different levels (protein and
RNA) [Rashidi et al., 2017; Salarini et al., 2015]. MiRNAs have
multiple biological roles in different processes within living
organisms [Mirzaei et al., 2017a; Rashidi et al., 2017]. Figure 1
illustrate a scheme of miRNA biogenesis. Multiple lines of evidence
indicated that miRNAs play important roles in initiation and
progression of various cancers [Mirzaei et al., 2016f,g; Mohammadi
et al., 2016b]. These molecules regulate different cellular and
molecular pathways includingWnt, Notch, TGF-b and play putative
roles in epithelial–mesenchymal transition (EMT). It is plausible that
some expression aberrations of miRNAsmight lead to initiation and/
or development of a variety of cancers [Mirzaei et al., 2016g,h;
Mohammadi et al., 2016b] (Table I). Various studies have been
revealed that miRNAs could be used as diagnostic, prognostic and
therapeutic biomarkers for various cancers. Therefore, monitoring of
miRNA expression patterns can assist the elucidation of the
biogenesis and biological function of miRNAs in different phases
of cancers.
MicroRNA AND MOLECULAR IMAGING IN CANCER
The miRNAs are known to regulate the expression of genes involved
in many cellular/and molecular pathways. The aberration of these
Fig. 1. A scheme of miRNA biogenesis.
JOURNAL OF CELLULAR BIOCHEMISTRY2 MicroRNAs-BASED IMAGING TECHNIQUES AND CANCER DIAGNOSIS
TABLE I. Various MiRNAs Involved in Cancer Pathogenesis





Melanoma miR-200c Down regulation ZEB1, DEF1, Nil-2-A I, II, III, IV/41 Xu et al, [2012]
miR-211 Down regulation MITF, AP1S2, SOX11, IGFBP5 I, II, III, IV/41 Xu et al. [2012]
miR-205 Down regulation E2F1, E2F5 I, II, III, IV/41 Xu et al. [2012]
miR-203 Down regulation E2F3 I, II, III, IV/41 Xu et al. [2012]
miR-33a Up regulation Pim-1, CDK6, cyclin D1 I-III/140 Friedman et al. [2012]
miR-33a Up regulation p53, c-Myc IIIB, IIIC, IV/59 Segura et al. [2010]
Lung miR-193b Up regulation MAPK, PI3K-AKT, p53, ErbB I, II/107 Nadal et al. [2015]
miR-301 Up regulation MAPK, PI3K-AKT, p53, ErbB I, II/107 Nadal et al. [2015]
miR-141 Up regulation MAPK, PI3K-AKT, p53, ErbB I, II/107 Nadal et al. [2015]
miR-200b Up regulation MAPK, PI3K-AKT, p53, ErbB I, II/107 Nadal et al. [2015]
Breast miR-21 Up regulation PDCD4, HIF1A 17 Qi et al. [2009]
miR-10b Up regulation HOXD10 23 Ma et al. [2007]
miR-155 Up regulation SOCS1, FOXO3 15 Jiang et al. [2010]
miR-373 Up regulation CD44 11 Huang et al. [2008]
miR-520c Up regulation CD44 11 Huang et al. [2008]
miR-125b Up regulation EPO, EPOR 42 Ferracin et al. [2013]; van Schooneveld
et al. [2015]
Liver miR-18 Up regulation – 22 Murakami et al. [2006]
miR-20 Up regulation – 22 Murakami et al. [2006]
miR-195 Down regulation – 22 Murakami et al. [2006]
miR-21 Up regulation – 20 Li et al. [2009]
miR-101 Down regulation – 20 Li et al. [2009]
miR-92 Up regulation – 4 Connolly et al. [2008]
Ovarian miR-21 Up regulation 38 Resnick et al. [2009]
miR-155 Down regulation 38 Resnick et al. [2009]
miR-30c-1-3p Up regulation 24 H€ausler et al. [2010]
miR-342-3p Down regulation 24 H€ausler et al. [2010]
miR-16 Up regulation 35 Suryawanshi et al. [2013]
let-7f Down regulation 360 Zheng et al. [2013]
Oral miR-21 Up regulation 60 Zahran et al. [2015]
miR-184 Up regulation 60 Zahran et al. [2015]
miR-145 Down regulation 60 Zahran et al. [2015]
miR-26a Down regulation TMEM184B 36 Fukumoto et al. [2015]
miR-26b Down regulation TMEM184B 36 Fukumoto et al. [2015]
miR-375 Down regulation 51 Lajer et al. [2011]
miR-31 Up regulation 51 Lajer et al. [2011]
Glioblastoma miR-23 Up regulation Mdm2, TSC1 Cell line Tang et al. [2011]
miR-10b Up regulation HOXD10, RhoC 20 Guessous et al. [2013]
miR-25 Up regulation Mdm2, TSC1 9/I, III Ciafre et al. [2005]
miR-16 Up regulation BCL2 Cell line Chaudhry et al. [2010]
miR-19a Up regulation 118 Jia et al. [2013]
miR-451 Down regulation PI3K/AKT Cell line Gal et al. [2008]
miR-145 Down regulation Oct4, SOX2 Cell line Koo et al. [2012]
Retinoblastoma miR-373 Up regulation 3 Yang and Mei, 2015]
miR-181a Down regulation CDKN1B 3 Yang and Mei, 2015]
miR-125b Down regulation CDK6, CDC25A 3 Yang and Mei, 2015]
let-7b Down regulation CDK6, CDC25A 3 Yang and Mei, 2015]
miR-25 Up regulation BCL2L1 3 Yang and Mei, 2015]
miR-18a BCL2L1 3 Yang and Mei, 2015]
miR-20a Up regulation BCL2L1 3 Yang and Mei, 2015]
Prostate miR-141 Up regulation 102 Kelly et al. [2015]
miR-145 Up regulation 102 Kelly et al. [2015]
miR-155 Up regulation 102 Kelly et al. [2015]
let7a Down regulation 102 Kelly et al. [2015]
miR-375 Up regulation 102 Kelly et al. [2015]
Colon let-7 Down regulation KRAS Cell line Graziano et al. [2010]
miR-29 Down regulation MMP2, DNMT3A/B Cell line Ding et al. [2011]
miR-30a-5P Down regulation DTL Cell line Baraniskin et al. [2012]
miR-34a Down regulation FRA1, SIRT1, MYC, BCL2 Cell line Schetter et al. [2012]
miR-17-92
cluster
Up regulation E2F1 Cell line Yu et al. [2012]
miR-95 Up regulation SNX1 Cell line Huang et al. [2011]
miR-135a/b Up regulation APC Cell line Luo et al. [2011]
Gastric miR-21 Up regulation RECK 59/I, II, III, IV Zhang et al. [2008]; Tsujiura et al. [2010];
Zheng et al. [2010]
miR-17-5p Up regulation 87/I, II, III, IV Tsujiura et al. [2010]; Wang et al. [2012]
miR-1 Up regulation MET 116/I, II, III, IV Liu et al. [2011]
miR-421 Up regulation 141/I, II, III, IV Zhou et al. [2012]; Wu et al. [2014]
miR-34 Up regulation MET 141/I, II, III, IV Zhou et al. [2012]; Wu et al. [2014]
miR-195-5p Down regulation In vivo Gorur et al. [2013]
miR-196a Down regulation Annexin A1, HMGA2, HOXA8 In vivo Tsai et al. [2012]
miR-203 Down regulation EMT activators 130/I, II, III, IV Imaoka et al. [2015]
let-7a Down regulation 69/I, II, III, IV Arabpour et al. [2016]
Hepatocellular
carcinoma
miR-373 Up regulation PPP6C 110 Wu et al. [2011]
miR-381 Up regulation 110 Murakami et al. [2013]
(Continued)
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genes could contribute to cancer initiation and progression. In
respect to the magnitude of miRNA genes in the pathogenesis and
progression of cancer, the utilization of suitable methods for
assessing miRNAs provide insight into new opportunities for cancer
treatment by modulating miRNA pathways and activities [Lee et al.,
2008; Hernandez et al., 2013].
There are various conventional miRNA detection strategies
including microarray, RT-PCR, and Northern blotting. Conventional
TABLE I. (Continued )





miR-130b Up regulation TP53INP1 57 Liu et al. [2012]; Wei et al. [2013]
miR-20a Up regulation 110/I, II, III Fan et al. [2013]; Wei et al. [2013]
miR-21 Up regulation C/EBPb, RhoB, PDCD4, PTEN 137/I, II, III Ura et al. [2009]; Xu et al. [2011];
Wei et al. [2013]; Zhou et al. [2011]
miR-122 Down regulation c-Myc, Bcl-w, ADAM-1, Wnt-1,
MTTP
90/B, C, D, A El-Garem et al. [2014]
miR-223 Down regulation STMN1 110/I, II, III Ura et al. [2009]; Xu et al. [2011];
Wei et al. [2013]; Zhou et al. [2011]
TABLE II. Various Techniques for Detecting MiRNAs in Cancer
Technique miRNA Type of cancer Expression in cancer Citation
BLI miR-21 Breast Up regulation Hernandez et al. [2013]
miR-221 Papillary thyroid carcinoma Up regulation Kim et al. [2008]
miR-9 Embryonic carcinoma Down regulation Ko et al. [2008]
miR-9 Embryonic carcinoma Down regulation Ko et al. [2008]
miR-124a Embryonic carcinoma Up regulation Ko et al. [2009a]
MB miR-155 Lung Up regulation Yao et al. [2012]
miR-10b Breast Up regulation Yigit et al. [2013]
miR-10b Adenocarcinomas Up regulation Yigit et al. [2013]
miR-1 – Up regulation Kang et al. [2015]
miR-26a – Down regulation Kang et al. [2015]
miR124a – Up regulation Kang et al. [2015]
miR-126 – Up regulation Kang et al. [2015]
miR-206 – Up regulation Kang et al. [2015]
miR-221 – Up regulation Kang et al. [2015]
miR-9 Down regulation Kang et al. [2015]
Microarray miR-136 Oral cancer Down regulation Momen-Heravi et al. [2014]
miR-147 Oral cancer Down regulation Momen-Heravi et al. [2014]
miR-1250 Oral cancer Down regulation Momen-Heravi et al. [2014]
miR-148a Oral cancer Down regulation Momen-Heravi et al. [2014]
miR-632 Oral cancer Down regulation Momen-Heravi et al. [2014]
miR-646 Oral cancer Down regulation Momen-Heravi et al. [2014]
miR-668 Oral cancer Down regulation Momen-Heravi et al. [2014]
miR-877 Oral cancer Down regulation Momen-Heravi et al. [2014]
miR-503 Oral cancer Down regulation Momen-Heravi et al. [2014]
miR-220a Oral cancer Down regulation Momen-Heravi et al. [2014]
miR-323-5p Oral cancer Down regulation Momen-Heravi et al. [2014]
miR-24 Oral cancer Up regulation Momen-Heravi et al. [2014]
miR-27b Oral cancer Up regulation Momen-Heravi et al. [2014]
let-7 family Breast Down regulation Litman et al. [2007]
miR-21 Breast Up regulation Litman et al. [2007]
miR-505-5p Breast Down regulation Matamala et al. [2015]
miR-125b-5p Breast Down regulation Matamala et al. [2015]
miR-21-5p Breast Up regulation Matamala et al. [2015]
miR-96-5p Breast Up regulation Matamala et al. [2015]
miR-576-5p, Glioblastoma Up regulation Dong et al. [2014]
miR-340 Glioblastoma Up regulation Dong et al. [2014]
miR-626 Glioblastoma Up regulation Dong et al. [2014]
miR-320 Glioblastoma Down regulation Dong et al. [2014]
let-7g-5p Glioblastoma Down regulation Dong et al. [2014]
miR-7-5P Glioblastoma Down regulation Dong et al. [2014]
RT-PCR miR-223 Gastric Up regulation Gorur et al. [2013]
miR-106b Gastric Up regulation Gorur et al. [2013]
miR-147 Gastric Up regulation Gorur et al. [2013]
miR-34a Gastric Up regulation Gorur et al. [2013]
miR-130b Gastric Up regulation Gorur et al. [2013]
miR-638 Gastric Down regulation Gorur et al. [2013]
miR-37 Gastric Down regulation Gorur et al. [2013]
miR18a Colon Up regulation Giraldez et al. [2013]
miR19a Colon Up regulation Giraldez et al. [2013]
miR15b, Colon Up regulation Giraldez et al. [2013]
miR29a Colon Up regulation Giraldez et al. [2013]
NGS miR-574-3p Breast Down regulation Krishnan et al. [2015]
miR-660-5p Breast Down regulation Krishnan et al. [2015]
BLI: bioluminescence imaging, MB: molecular beacon, NGS: Next Generation Sequencing, RT-PCR: Reverse transcription polymerase chain reaction.
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detection methods are associated with some limitations which
indicate a necessity for devising and deploying high-throughput
noninvasive repetitive and real-time imaging systems for the
detection of miRNAs in preclinical and clinical settings [German
et al., 2008; Ko et al., 2009a; Sun et al., 2010]. In the following
section, we will describe recently developed miRNA imaging
strategies such as the various bioluminescence systems, ﬂuorescent
imaging approaches, as well as magnetic resonance imaging. In
addition, both the advantages and inherent inefﬁciencies of various
imaging systems are also described.
Recent signiﬁcant advancement in reporter-based optical imaging
systems has provided the opportunities of noninvasive and repeated
real-time analysis of the miRNA gene expression in living cells. These
miRNA imaging approaches offer a better elucidation of the biogenesis
and biological function of miRNAs in vivo as well as miRNAs
expression proﬁle in human diseases [Gambhir et al., 1999; Blasberg,
2003;Wang et al., 2003]. These imaging techniques could, for example,
provide better data on intact biological context than the “snapshots”
provided by in vitro assays [Lee et al., 2008; Hernandez et al., 2013].
Several studies indicated that there are different categories for
miRNA imaging. One of the main categories is based on nano-
particles, Bioluminescent imaging (BLI), ﬂuorescent proteins (FPs),
and molecular beacon (MB) imaging.
Despite of much advancement in theﬁeld of imaging for detecting
of miRNAs, this ﬁeld is still in its infancy. Modern and new imaging
techniques provide a new horizon for the study of various targets and
molecules in different levels in living cells [Ottobrini et al., 2006; Lee
et al., 2008; Hernandez et al., 2013].
Some studies have been used bioluminescent reporter proteins
such as Fireﬂy luciferase (Fluc) and Gaussia luciferase (Gluc) for the
imaging of various miRNAs in living cells [Ottobrini et al., 2006].
Gaussia luciferase utilizes coelenterazine as a substrate and emits
light with a peak at 480 nm with a broad spectrum extending to
600 nm. Fireﬂy luciferase emits light with a peak at 562 nm.
D-luciferin serves as a good substrate for Fireﬂy luciferase [Gould
and Subramani, 1988; Tannous et al., 2005].
Other systems are reporter-based miRNA detection imaging
systems. In the presence of miRNA, these systems demonstrate a
dropping in reporter signals which is correlated with translational
repression of its target mRNA [Ko et al., 2008, 2009b; Kim et al.,
2009]. These imaging systems could facilitate potential applications
for assessing ofmiRNA levels during biological processes such as cell
growth and differentiation and the cell cycle in living animals [Ko
et al., 2009b]. For instance, these techniques could be utilized to
detect and monitor differentiation patterns of stem cells by miRNA
(cell-speciﬁc) expression in vivo or to detect miRNAs involved in
cancer progression, for example, miR-221 and miR-21 [Ko et al.,
2009b]. Table II represents a variety ofmiRNAswhich are detected by
various techniques.
CONCLUDING REMARKS
MicroRNAs are a class of small non-coding RNA species, known as
miRNAs, which control gene expression across various physiological
and pathological processes. Their aberrant expression may be involved
in human diseases. Among human diseases, it has been shown that
miRNAs are aberrantly expressed or mutated in cancer, indicating that
they may play a role as a new class of oncogenes or tumor suppressor
genes. As the miRNA ﬁeld continues to grow and evolve, it is an
important step to develop efﬁcient tools for rapid, speciﬁc, sensitive,
and noninvasive imaging detection of miRNAs toward understanding
the functions ofmiRNAs in various regulatory pathways in vivo, which
consequently effect on the development of miRNA-based diagnostic
and therapeutic assays at molecular level and new targets in drug
discovery. In contrast to conventional imaging systems, newmolecular
imaging systems such as reported-based optical imaging systems are
multiplex and have high speciﬁcity against other family RNAs and
minimum sample manipulation and could be utilized for studying
living systems.However, oncenewgenerations of imaging systems (i.e.,
reporter-based imaging) involve genetic modiﬁcation in studied
subjects; there are still some concerns regarding their translation into
clinical practice. In conclusion, molecular imaging techniques are
robust tools for high-throughput noninvasive repetitive and real-time
monitoring of biogenesis, localization patterns, and biological function
of miRNAs in vivo as well as miRNAs expression proﬁle in human
diseases particularly cancer. Such imaging systems will deepen our
knowledge of miRNAs expression patterns and their biological
functions in various tumorigenic regulatory networks in vivo, which
eventually effect on the development of miRNA-based diagnostic and
therapeutic assays and new targets in cancer drug discovery.
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